- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04568603
Islatravir and Methadone Pharmacokinetics (MK-8591-029)
March 28, 2023 updated by: Merck Sharp & Dohme LLC
A Clinical Trial to Study the Effect of a Single Dose of Islatravir (MK-8591) on the Pharmacokinetics of Methadone
The present study is designed to determine the effect of islatravir (ISL) [MK-8591] on methadone pharmacokinetics (PK).
The primary objective is to assess whether ISL impacts the area under the plasma concentration time curve from dosing to 24 hours postdose (AUC0-24) of S-methadone and R-methadone in participants on oral methadone therapy.
It is hypothesized that the plasma AUC0-24hr for S- and R-methadone will be similar after methadone alone compared to methadone and ISL 60 mg coadministration.
Study Overview
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Hollywood, Florida, United States, 33024
- Research Centers of America, LLC ( Site 0002)
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- PRA Health Sciences ( Site 0001)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Has a body mass index (BMI) > 18 and ≤ 35 kg/m^2
- Is in good health based on laboratory safety tests obtained at the screening visit and prior to administration of study drug
- Is in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECGs) performed prior to randomization.
- Has a negative human immunodeficiency virus (HIV) antigen/antibody test at screening
- For male participants, follows contraception guidance consistent with local regulations
- For female participants:
- Is not a woman of childbearing potential (WOCBP) or
- Is a WOCBP and using acceptable contraception or is abstinent
- Is reliably participating in a methadone maintenance program for at least two (2) months prior to Day 1
- Agrees to not change their current maintenance methadone dose of 20-200 mg administered as a single daily dose
Exclusion Criteria:
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- Is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years
- Has a history of cancer (malignancy)
- Has a history of significant multiple and/or severe allergies (eg, food, drug, latex) or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or non-prescription drugs or food
- Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the screening visit
- With the exception of methadone, is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to the first dose of the 14-day methadone maintenance run-in phase prior to Day 1, throughout the trial, until the AE follow-up call (Day 16)
- Has participated in another investigational study within 4 weeks (or 5 half-lives) prior to the prestudy (screening) visit.
- Has a QTc interval >450 msec (males) or >470 msec (females), has a history of risk factors for Torsades de Pointes (eg, heart failure/cardiomyopathy or family history of long QT syndrome), has uncorrected hypokalemia or hypomagnesemia, is taking concomitant medications that prolong the QT/QTc interval other than methadone
- Does not limit smoking to no more than 10 cigarettes per day while in the clinical research unit (CRU)
- Consumes greater than 3 glasses of alcoholic beverages per day
- Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day
- With the exception of tetrahydrocannabinol (THC), has a positive screen for drugs with a high potential for abuse such as cocaine, amphetamines, methylenedioxymethamphetamine (MDMA), barbiturates, benzodiazepines (with the exception noted in exclusion criteria 7), or opiates/opioids on Day -1
- Presents any concern by the investigator regarding safe participation in the study or for any other reason the investigator considers the participant inappropriate for participation in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Methadone + ISL
Methadone-maintained participants (20 to 200 mg [locally-provided] once daily [QD] from Day -14 to Day -1 and Day 10 to Day 15) receive methadone 20 to 200 mg QD on Day 1 to Day 9; ISL 60 mg is co-administered with methadone on Day 2.
|
ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The AUC0-24 of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Dose-Normalized AUC0-24 of S-Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The AUC0-24hr of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-Normalized Maximum Plasma Concentration (Cmax) of R-Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The Cmax of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Dose-Normalized Plasma Concentration 24 Hours Postdose (C24) of R-Methadone
Time Frame: Days 1 and 2: 24 hours postdose
|
The C24 of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: 24 hours postdose
|
Time to Maximum Plasma Concentration (Tmax) of R-Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The Tmax of R-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Dose-Normalized Cmax of S-Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The Cmax of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Dose-Normalized C24 of S-Methadone
Time Frame: Days 1 and 2: 24 hours postdose
|
The C24 of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: 24 hours postdose
|
Tmax of S-Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The Tmax of S-methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Dose-Normalized AUC0-24 of Total Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The AUC0-24hr of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Dose-Normalized Cmax of Total Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The Cmax of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Dose-Normalized C24 of Total Methadone
Time Frame: Days 1 and 2: 24 hours postdose
|
The C24 of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
Back-transformed least-squares mean and confidence interval from mixed effects model were performed on natural log-transformed values; data show the geometric least squares mean.
|
Days 1 and 2: 24 hours postdose
|
Tmax of Total Methadone
Time Frame: Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
The Tmax of total methadone was determined on Day 1 (methadone) and Day 2 (methadone + ISL).
|
Days 1 and 2: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose
|
Number of Participants With Adverse Events (AEs) Following Methadone + ISL Coadministration
Time Frame: Up to 16 days
|
The number of participants with AEs will be determined for 14 days after coadministration of methadone and ISL on Day 2.
|
Up to 16 days
|
Number of Participants Discontinuing Study Therapy Due to AEs Following Coadministration of Methadone and ISL
Time Frame: Up to 15 days
|
The number of participants discontinuing study therapy due to AEs after methadone + ISL on Day 2 will be determined.
|
Up to 15 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 16, 2020
Primary Completion (Actual)
July 9, 2021
Study Completion (Actual)
July 9, 2021
Study Registration Dates
First Submitted
September 23, 2020
First Submitted That Met QC Criteria
September 23, 2020
First Posted (Actual)
September 29, 2020
Study Record Updates
Last Update Posted (Estimated)
December 11, 2023
Last Update Submitted That Met QC Criteria
March 28, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8591-029
- MK-8591-029 (Other Identifier: Merck Protocol Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1 Infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on Islatravir
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedHIV-1 InfectionUnited States, Italy, Russian Federation, South Africa, Thailand
-
Merck Sharp & Dohme LLCCompletedHIV-1 InfectionUnited States, Chile, France, United Kingdom
-
Merck Sharp & Dohme LLCActive, not recruitingHIV InfectionUnited States, Russian Federation, Argentina, Australia, Canada, Chile, Colombia, Israel, Japan, New Zealand, Puerto Rico, South Africa, Switzerland, Taiwan, United Kingdom
-
Merck Sharp & Dohme LLCCompletedHIV-1 InfectionUnited States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, Korea, Republic of, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
-
Merck Sharp & Dohme LLCActive, not recruitingHIV-1 InfectionUnited States, Argentina, Canada, Chile, Colombia, France, Germany, Israel, Italy, Japan, South Africa, Spain, Taiwan
-
Merck Sharp & Dohme LLCCompletedHuman Immunodeficiency Virus (HIV) InfectionUnited States, Germany
-
Merck Sharp & Dohme LLCCompletedHuman Immunodeficiency Virus (HIV) InfectionUnited States
-
Merck Sharp & Dohme LLCWithdrawnHuman Immunodeficiency Virus (HIV) Infections
-
Merck Sharp & Dohme LLCActive, not recruitingHIV InfectionUnited States, Australia, Canada, Chile, Colombia, France, Italy, Japan, New Zealand, Poland, Russian Federation, South Africa, Spain, Switzerland, United Kingdom